AstraZeneca Products - Respiratory & Inflammation - Asthma, COPD, respiratory diseases

Respiratory & Inflammation

The World Health Organisation estimates that 150 million people worldwide suffer from asthma and that chronic obstructive pulmonary disease is the fourth greatest cause of death worldwide.

AstraZeneca’s respiratory portfolio includes Symbicort, a combination of the inhaled steroid budesonide and the long-acting bronchodilator formoterol delivered via the gold-standard dry-powder inhaler Turbuhaler. Symbicort is the only inhaled steroid/bronchodilator combination inhaler that enables asthma patients to adjust their treatment dose to control the natural variations in their disease using the same inhaler.

Product range

More information about our products is available by clicking on the names below.

Brand Name	Generic Name
Accolate, Accoleit, Vanticon	zafirlukast
Bambec, Oxeol	bambuterol
Bricanyl	terbutaline
Oxis	formoterol
Pulmicort, Spirocort	budesonide
Rhinocort	budesonide
Symbicort	budesonide/formoterol
Delivery devices for AstraZeneca products
NebuChamber
Turbuhaler

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.